CML Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
I
Recruiting
  • Chronic Myeloid Leukemia
  • +3 more
    • Antwerpen, Belgium
    • +18 more
    2022-03-31
    Mar 31, 2022
    N
    Active, not recruiting
    • CML
    • +3 more
    • Asciminib add-on
    • +2 more
    • Augusta, Georgia
    • +29 more
    2022-02-03
    Feb 3, 2022
    A
    Recruiting
    • Folate
    • +2 more
      • Nantong, China
        Affliated Hospital of Nantong University
      2021-12-13
      Dec 13, 2021
      N
      Completed
      • CML
      • Imatinib
      • high-dose imatinib
      • Seoul, Korea, Republic of
        Novartis Investigational Site
      2021-03-09
      Mar 9, 2021
      N
      Completed
      • CML
      • GIST
        • Taipei, Taiwan
          National Taiwan University Hosptial
        2020-08-07
        Aug 7, 2020
        P
        Completed
        • CML
        • 200 Mg capsules of bosutinib in Water solution
        • +13 more
        • Brussels, Belgium
          Pfizer Clinical Research Unit
        2020-07-08
        Jul 8, 2020
        A
        Terminated
        • ALL
        • +3 more
        • Rapamycin + high dose etoposide and cytarabine
        • Philadelphia, Pennsylvania
          University of Pennsylvania Abramson Cancer Center
        2020-04-15
        Apr 15, 2020
        N
        Completed
        • Hodgkin Lymphoma
        • +8 more
        • Stem cell transplantation
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        2019-12-13
        Dec 13, 2019
        A
        Completed
        • Myeloid Leukemias
        • +3 more
        • Rapamycin, Mitoxantrone, Etoposide, Cytarabine
        • Rapamycin + MEC
        • Philadelphia, Pennsylvania
          University of Pennsylvania Abramson Cancer Center
        2019-07-10
        Jul 10, 2019
        N
        Completed
        • CML
        • +3 more
        • Seoul, Korea, Republic of
          St. Mary hospital, Catholic medical center
        2017-02-24
        Feb 24, 2017
        U
        Completed
        • CML
        • +6 more
        • Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells
        • Observation Arm
        • Philadelphia, Pennsylvania
          University of Pennsylvania
        2016-08-17
        Aug 17, 2016
        S
        Completed
        • AML
        • +3 more
        • STA-9090 (ganetespib)
        • Boston, Massachusetts
        • +2 more
        2014-09-17
        Sep 17, 2014
        U
        Completed
        • CML
        • +5 more
          • San Francisco, California
            University of California San Francisco
          2013-08-01
          Aug 1, 2013
          R
          Unknown status
          • CML
          • Treatment modification based on molecular response at 3 months
          • Petah tikva, Israel
            Rabin Medical Center
          2013-01-07
          Jan 7, 2013
          C
          Completed
          • AML
          • +2 more
          • CYT107 - Recombinant glycosylated human interleukin 7.
          • rhIL-7 (CYT107)
          • New York, New York
            Memorial Sloan-Kettering Cancer Institute
          2012-07-25
          Jul 25, 2012
          D
          Completed
          • Hematologic Malignancy
          • +6 more
          • CD+8 T cell depletion
          • Boston, Massachusetts
          • +1 more
          2012-03-15
          Mar 15, 2012
          S
          Unknown status
          • AML
          • +4 more
          • fludarabine phosphate, busulfan
          • Seoul, Korea, Republic of
            Dong Hwan Kim
          2008-12-29
          Dec 29, 2008